Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/I-MAB-95388118/news/I-Mab-Announces-IND-Approval-from-China-NMPA-for-Phase-2-Clinical-Trial-of-Enoblituzumab-in-Combinat-37425401/?utm_source=whatsapp&utm_medium=social&utm_campaign=share